Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING NA

The ACHIEVE Trial: Achieving Longer Gestation in Preeclampsia Via Antihypertensive Therapy.

NCT05676476 · View on ClinicalTrials.gov ↗

Study Summary

The Achieve Trial is a randomized clinical trial to test whether lowering blood pressure to less than 140/90 mmHg in women with hypertensive disorders of pregnancy will prolong pregnancy.

Interventions

  • DRUG Antihypertensive treatment

Study Locations (2)

Alabama

  • University of Alabama at Birmingham — Birmingham

Louisiana

  • Oschner — New Orleans

Trial Details

FieldValue
Enrollment Target 132 participants
Start Date 2023-02-14
Est. Completion 2027-06
Phase NA

Sponsor

University of Alabama at Birmingham

1,315 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05676476

The ClinicalTrials.gov registry entry for NCT05676476 describes a study currently listed as recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 132 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,315 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 3 conditions, with Preeclampsia appearing as the primary indexed condition, and to 1 intervention — of which Antihypertensive treatment is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT05676476 reports 2 study locations spanning 2 distinct geographic areas — top geographies include Alabama, Louisiana. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT05676476 about?

NCT05676476 is a clinical study titled "The ACHIEVE Trial: Achieving Longer Gestation in Preeclampsia Via Antihypertensive Therapy.". The Achieve Trial is a randomized clinical trial to test whether lowering blood pressure to less than 140/90 mmHg in women with hypertensive disorders of pregnancy will prolong pregnancy.

What is the current status of trial NCT05676476?

This trial is currently recruiting. It is a NA study. The enrollment target is 132 participants. The study started on 2023-02-14. Estimated completion is 2027-06.

What conditions does trial NCT05676476 study?

This clinical trial studies the following conditions: Preeclampsia, Gestational Hypertension, Hypertensive Disorder of Pregnancy. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT05676476?

The interventions under investigation include: Antihypertensive treatment (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT05676476?

This trial is sponsored by University of Alabama at Birmingham, which has 1,315 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT05676476 being conducted?

This trial has 2 study locations across Alabama, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial